Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
AChE
|
---|---|
ln Vitro |
Nodakenin is a dose-regulated inhibitor of AChE activity, with an IC50 value of 84.7 μM[1].
|
ln Vivo |
The maze avoidance test and the Y-maze test demonstrate that nodakenin (10 mg/kg, po) can overcome the cognitive impairment caused by scopolamine [1]. The maze avoidance test and the Y-maze test demonstrate that nodakenin (10 mg/kg, po) can overcome the cognitive impairment caused by scopolamine [1]. Morris water maze training test results show that nodakenin (10 mg/kg, po) decreases escape delay [1].
|
Animal Protocol |
Animal/Disease Models: Male ICR mouse
Doses: 2.5, 5, 10 and 20 mg/kg Route of Administration: po, single dose Experimental Results: Scopolamine-induced stepwise latency reversal. |
References |
[1]. Kim DH, et al. Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice. Life Sci. 2007 May 1;80(21):1944-50.
[2]. Xiong Y, et al. The effects of nodakenin on airway inflammation, hyper-responsiveness and remodeling in a murine model of allergic asthma. Immunopharmacol Immunotoxicol. 2014 Oct;36(5):341-8. |
Molecular Formula |
C20H24O9
|
---|---|
Molecular Weight |
408.3992
|
Exact Mass |
408.142
|
CAS # |
495-31-8
|
Appearance |
White to off-white solid
|
Density |
1.5±0.1 g/cm3
|
Boiling Point |
635.4±55.0 °C at 760 mmHg
|
Melting Point |
melting at 216°
|
Flash Point |
225.4±25.0 °C
|
Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
Index of Refraction |
1.651
|
LogP |
-0.66
|
SMILES |
O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])C(C([H])([H])[H])(C([H])([H])[H])[C@@]1([H])C([H])([H])C2C([H])=C3C([H])=C([H])C(=O)OC3=C([H])C=2O1
|
InChi Key |
HXCGUCZXPFBNRD-DNLMCPORSA-N
|
InChi Code |
InChI=1S/C20H24O9/c1-20(2,29-19-18(25)17(24)16(23)13(8-21)28-19)14-6-10-5-9-3-4-15(22)27-11(9)7-12(10)26-14/h3-5,7,13-14,16-19,21,23-25H,6,8H2,1-2H3/t13-,14-,16-,17+,18-,19+/m1/s1
|
Chemical Name |
(2R)-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~244.86 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4486 mL | 12.2429 mL | 24.4858 mL | |
5 mM | 0.4897 mL | 2.4486 mL | 4.8972 mL | |
10 mM | 0.2449 mL | 1.2243 mL | 2.4486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.